oral semaglutide microdose Microdosing Chart: A Monthly Dose Guide For Josie Patients GLP-1 Microdosing 2026: 0.1mg Chart

As of April 1, 2026, the FDA issued updated guidance stating that the GLP-1 supply is stabilizing and, with that, prohibiting pharmacies and outsourcing facilities from mass-producing copycat compounded versions of these medications

doi: 10.2337/dc12-2454 [DOI] [PMC free article] [PubMed] [Google Scholar] 217

The FDA maintains a page on interstate compounding restrictions that is worth reviewing [3]

While anyone who knows how the evolution of GLP-1s will play out, there are a few certainties: The drugs will get cheaper as more competition is introduced and a pill version becomes widely available Demand for GLP-1s will continue to increase exponentially as awareness of their effectiveness increases Coverage will increase as Wegovy and other GLP-1 inhibitors get approved for additional use cases such as cardiovascular health and addiction Finally, they are only going to get more effective

For a long time, weight and appetite were mostly discussed through the lens of willpower, calories and discipline

Oncology remains a major driver, with ADCs and nextgeneration constructs (like multi-specific and dual-payload ADCs) requiring highly specialized containment and analytical capabilities